CHMP gives positive opinion for Sanofi’s and Regeneron’s rheumatoid arthritis drug

European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorization of Sanofi and Regeneron Pharmaceuticals joint developed product Kevzara (sarilumab), recommending its approval for use in adult patients with moderately to severely active rheumatoid arthritis.

Read more